{"denoms":[{"counts":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"19"}],"units":"Participants"}],"groups":[{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"BG000","title":"Breast"},{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"BG001","title":"Prostate"},{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"BG002","title":"Colorectal"},{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"BG003","title":"Non-Small Cell Lung Cancer (NSCLC)"},{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"BG004","title":"Small-Cell Lung Cancer (SCLC)"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.60","value":"61.8"},{"groupId":"BG001","spread":"6.31","value":"65.4"},{"groupId":"BG002","spread":"13.68","value":"64.2"},{"groupId":"BG003","spread":"3.21","value":"64.7"},{"comment":"Only one participant analyzed","groupId":"BG004","spread":"NA","value":"54.0"},{"groupId":"BG005","spread":"8.46","value":"63.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"11"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"8"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"11"}]}],"title":"Not Collected"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.53","value":"70.6"},{"groupId":"BG001","spread":"7.46","value":"85.2"},{"groupId":"BG002","spread":"8.63","value":"72.6"},{"groupId":"BG003","spread":"23.38","value":"72.1"},{"comment":"Only one participant analyzed","groupId":"BG004","spread":"NA","value":"62.8"},{"groupId":"BG005","spread":"12.64","value":"74.8"}]}]}],"description":"Baseline is defined as the last measurement prior to Investigational Medicinal Product (IMP) administration.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Baseline Weight","unitOfMeasure":"kilogram (kg)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.21","value":"165.6"},{"groupId":"BG001","spread":"5.94","value":"175.4"},{"groupId":"BG002","spread":"6.23","value":"170.4"},{"groupId":"BG003","spread":"3.51","value":"165.7"},{"comment":"Only one participant analyzed","groupId":"BG004","spread":"NA","value":"168.0"},{"groupId":"BG005","spread":"10.7","value":"169.6"}]}]}],"description":"Baseline is defined as the last measurement prior to Investigational Medicinal Product (IMP) administration.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Baseline Height","unitOfMeasure":"centimeter (cm)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"4.563","value":"25.84"},{"groupId":"BG001","spread":"3.202","value":"27.79"},{"groupId":"BG002","spread":"1.514","value":"24.90"},{"groupId":"BG003","spread":"7.552","value":"26.04"},{"comment":"Only one participant analyzed","groupId":"BG004","spread":"NA","value":"22.25"},{"groupId":"BG005","spread":"3.970","value":"25.95"}]}]}],"description":"Baseline is defined as the last measurement prior to Investigational Medicinal Product (IMP) administration.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Baseline Body Mass Index","unitOfMeasure":"kilogram per square metre (kg/m^2)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"}],"title":"IIIA"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"}],"title":"IIIC"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"16"}],"title":"IV"}]}],"description":"The overall diagnostic stage uses the stage at screening visit and the Tumour, Node, Metastasis (TNM) staging uses the latest available stage. Stage III indicates a locally advanced cancer that is likely to grow and spread; stage IIIA = the cancer has spread into nearby tissues; stage IIIC = the cancer cells across the tumor are poorly differentiated, meaning they look very different from healthy cells. Stage IV means that the cancer has spread to distant parts of the body and may be called advanced or metastatic cancer.","paramType":"COUNT_OF_PARTICIPANTS","title":"Diagnostic Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"64.61","value":"117.3"},{"groupId":"BG001","spread":"74.48","value":"50.5"},{"groupId":"BG002","spread":"25.40","value":"24.3"},{"groupId":"BG003","spread":"1.46","value":"1.6"},{"comment":"Only one participant analyzed","groupId":"BG004","spread":"NA","value":"1.1"},{"groupId":"BG005","spread":"65.32","value":"50.9"}]}]}],"description":"Time from initial diagnosis (months) is calculated as (date of IMP administration - date of initial diagnosis + 1)/30.4375.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Time from Initial Diagnosis of Primary Disease","unitOfMeasure":"Months"}],"populationDescription":"Full Analysis Set (FAS) = all subjects who enter the study and receive the \\[68Ga\\]-NeoBOMB1 dose."}